Emerging evidence suggests that sphingolipids may be involved in type 2 diabetes. However, the exact signaling defect through which disordered sphingolipid metabolism induces β-cell dysfunction remains unknown. The current study demonstrated that sphingosine-1-phosphate (S1P), the product of sphingosine kinase (SphK), is an essential factor for maintaining β-cell function and survival via regulation of mitochondrial action, as mediated by prohibitin (PHB).
INTRODUCTION
Insulin secretion is the main way through which pancreatic β-cells maintain glucose homeostasis, but it is impaired by chronic exposure to elevated levels of glucose and free fatty acids [1, 2] . Pancreatic β-cell impairment results in hyperglycemia and eventually leads to the onset of type 2 diabetes, suggesting that the preservation of β-cell function is important for curing and preventing type 2 diabetes [3] .
Despite extensive studies on the protection of pancreatic β-cells against glucolipotoxicity, the underlying mechanism of β-cell dysfunction and apoptosis is not completely understood. Ceramide, a sphingolipid metabolite, has been established as a mediator of β-cell dysfunction and apoptosis [4, 5] . In pancreatic islets, incubation with palmitate induced ceramide accumulation through an increase in cellular levels of long-chain acyl-coenzyme A, leading to the inhibition of insulin gene transcription [6, 7] and activation of apoptotic signaling [8] . Moreover, it has been reported that ceramide was associated with endoplasmic reticulum (ER) stress and mitochondrial abnormality in β-cells [9] . In the ER, ceramide is reversibly converted to sphingosine by alkaline ceramidases, but most of it is reconverted to ceramide due to its instability, and some sphingosine is used to generate sphingosine-1-phosphate (S1P) [10] . S1P was recently found to be a mediator of β-cell survival and insulin secretion. S1P was found to regulate glucose-stimulated insulin secretion (GSIS) in mouse insulinoma 6 (MIN6) cells and pancreatic islets [11] , and the loss of sphingosine kinase (SphK) promoted β-cell death in obese mice [12] .
In pancreatic β-cells, mitochondria are closely related with the secretory mechanism. Mitochondria generate adenosine triphosphate (ATP), and the closure of K-ATP channels induces cell membrane depolarization and exocytosis. Moreover, the depletion or specific deletion of mitochondrial DNA in pancreatic β-cells results in the onset of diabetes in animal models, showing that β-cell dysfunction is related to increased oxidative stress and impaired mitochondrial morphology [13] [14] [15] . Mitochondrial mechanisms are regulated by various factors. Prohibitin (PHB) is localized in the mitochondrial inner membrane and is associated with mitochondrial function [16] . Deletion of PHB damages mitochondrial morphology and reduces membrane potential and complex I activity [17, 18] . The anti-inflammatory effect of PHB was demonstrated in intestinal epithelial cells [19] , and it was also suggested that PHB functioned as a transcription factor [20] and mitochondrial chaperone [21] . Moreover, it has been reported that a specific deficiency of PHB in β-cells induced mitochondrial dysfunction and β-cell loss, and finally caused the failure of glucose homeostasis [22] .
Although increasing evidence supports the role of S1P in β-cell preservation, the cellular mechanism of how S1P acts to improve GSIS and survival remains unknown. This study investigated the role of S1P in maintaining β-cell homeostasis, focusing on the regulation of mitochondrial mechanisms and PHB.
METHODS
Cell culture, treatment, and transfection MIN6 cell lines were maintained in Dulbecco's Modified Eagle's medium (DMEM) containing 25 mmol/L glucose, mixed with heat-inactivated 10% fetal bovine serum, 100 IU/mL penicillin, 50 µg/mL streptomycin, and 50 µM 2-mercaptoethanol (Life Technologies Corporation, Paisley, UK), in a 37°C humidified incubator with 5% CO2. At 50% confluence, the cells were incubated in serum-free media with a sphingosine kinase inhibitor (SphKi; 15 µM) and/or S1P (D18:1, 10 µM) for 48 hours. For silencing of genes targeting PHB (GGAGUUCACAGAG-GCAGUATT) or SPHK (SPHK1: CGAGCAGGUGACU-AAUGAATT and UUCAUUAGUCACCUGCUCGTA; SPHK2: CAGGCTGCTCATATTGGTCAA and TAGGCTAAGATC-TATCATTTA), small interfering RNAs (siRNAs) were transfected into MIN6 cells using the Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific, Carlsbad, CA, USA), according to the manufacturer's instructions. This study was approved by the Institutional Animal Care and Use Committee of Kangbuk Samsung Hospital (IACUC 2014-10-075).
Poly (adenosine diphosphate ribose) polymerase activity assay A universal colorimetric poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) assay kit (Trevigen, Gaithersbug, MD, USA) was used to determine PARP activity. This kit was based on an intermixture of biotinylated ADP-ribose onto histone proteins. Cell lysates from MIN6 cells were loaded onto a histone-coated 96-well plate and incubated with biotinylated poly-ADP-ribose solution. After 1 hour, horseradish peroxidase and colorimetric substrates were added, and then absorbance was measured in a spectrophotometer at 450 nm.
RNA extraction and real-time polymerase chain reaction analysis Total RNA was extracted with TRIzol (Life Technologies, Carlsbad, CA, USA). The first strand of complementary DNA was synthesized by oligo(dT)-primed reverse transcription using an RT enzyme mix (Thermo Fisher Scientific, Rockford, IL, USA), and applied as a template for a real-time polymerase chain reaction (PCR) assay with SYBR green I Master (Roche Diagnostics, Indianapolis, IN, USA) and primers for insulin 1 (INS1) (sense 5′-CCCTTAGTGACCAGCTATAATCAGAGA-3′ and
Immunoblotting assay
Total protein from MIN6 cells was prepared using radioimmunoprecipitation assay (RIPA) buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA) with protease and phosphatase inhibitors. The proteins were separated in 4% to 12% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, and transferred to polyvinylidene difluoride membranes. Several proteins were detected and measured with antibodies for S1P, phosphor-stress activated protein kinase (SAPK)/ c-Jun N-terminal kinase (JNK) (T183/Y185), SAPK/JNK, cleaved caspase-3 (D175), total caspase-3, β-actin (Cell Signaling Technology, Danvers, MA, USA), pancreatic and duodenal homeobox 1 (Pdx-1, Millipore, Temecula, CA, USA), lamin B1, mitofusin 1 (MFN1, Abcam, Cambridge, MA, USA), mitochondrial dynamin-like GTPase (OPA1, BD Biosciences, San Diego, CA, USA), oxidative phosphorylation (OxPHOS) complex cocktail (Invitrogen, Rockford, IL, USA), and PHB (Santa Cruz Biotechnology).
Detection of the mitochondrial membrane potential
The mitochondrial membrane potential (MMP) was measured using cell-permeant cationic red orange fluorescent dye. MIN6 cells were incubated with 100 ng/mL tetramethylrhodamine ethyl ester (TMRE, Molecular Probes Inc., Eugene, OR, USA) and 10 ng/mL Hoechst (Molecular Probes Inc.) for 25 minutes at 37°C, followed by washing with phosphate-buffered saline for 5 minutes twice. Stained cells were imaged with an Olympus BX52 microscope (Olympus Optical Co., Tokyo, Japan), and the intensity of the red fluorescent dye was measured in ImageJ software to quantify the MMP.
Measurement of cellular ATP content
The intracellular ATP content was quantitatively determined using a colorimetric ATP assay kit (Abcam) according to the manufacturer's instructions. Cells were incubated with serum-free media for 1 hour, and then media was replaced with fresh media. After treatment with a detecting solution for 20 minutes, cells were lysed. ATP content was normalized to the total protein concentration.
Measurement of oxygen consumption
Oxygen consumption was measured using a MitoXpress Xtra Oxygen Consumption Assay Kit (Luxcel Bioscience, Cork, Ireland) according to the manufacturer's instructions. Briefly, MIN6 cells were seeded in a black and clear-bottom 96-well tissue culture plate and grown for 72 hours. At 50% to 70% confluence, 10 μL of MitoXpress Xtra solution was added to cells with 150 μL of fresh medium, and oxygen consumption was measured at the wavelength of 410 nm every 5 minutes for an hour.
Statistical analysis
In the present study, all statistical analyses were performed using PASW version 17 (SPSS Inc., Chicago, IL, USA). One-way analysis of variance was used to evaluate the statistical significance of differences among mean values in different experimental groups, and a P value <0.05 was considered to indicate statistical significance unless otherwise indicated.
RESULTS

Deficiency of sphingosine-1-phosphate induces β-cell dysfunction and apoptosis
To investigate the role of S1P in β-cells, we manipulated cellular S1P levels by treatment with a SphKi (15 μM) and/or S1P (d18:1; 10 μM). MIN6 cells were incubated with SphKi, which reduced cellular S1P levels to a remarkable extent, and co-treatment with S1P conserved the S1P level (Fig. 1A) . The lack of S1P induced by SphKi treatment was accompanied by apoptosis, as shown by increased cleaved caspase-3, phosphorylated JNK, and PARP activity. In contrast, preservation of the cellular S1P levels greatly ameliorated apoptosis (Fig. 1A-C) . Insulin expression and secretion was also affected by cellular S1P levels. The decrease of INS1 and nuclear Pdx1 induced by SphKi treatment was significantly attenuated by co-treatment with S1P, and 25 mmol/L GSIS also recovered due to S1P treatment (Fig. 1D-F) . These results suggest that S1P, a signaling molecule of sphingolipid metabolism, is essential for maintaining β-cell function and viability.
Sphingosine-1-phosphate is involved in mitochondrial dynamics and function
As abundant evidence has indicated that SphK and S1P are essential factors for maintaining mitochondrial function [23, 24] , we examined the involvement of S1P in mitochondrial dynamics and function in pancreatic β-cells. We detected and analyzed the MMP by TMRE staining, and the red fluorescent signals indicating the strength of the MMP were significantly decreased by SphKi treatment (Fig. 2A, B) , and the expression of OPA1 and Mfn1, which are factors regulating mitochondrial fusion and fission, was also decreased by SphKi treatment (Fig. 2C, D) . Deficiency of cellular S1P strongly repressed mitochondrial function. The expression of mitochondrial OxPHOS-related proteins was affected by cellular S1P levels. In particular, Ox-PHOS complex IV was significantly decreased by SphKi treatment (Fig. 2E, F) . Moreover, cellular ATP content and the oxygen consumption rate were also down-regulated by SphKi treatment. Supplementation with S1P caused mitochondrial dynamics and function to largely recover, suggesting that S1P closely regulates mitochondrial action in β-cells. www.e-enm.org 407 Fig. 2 . Lack of sphingosine-1-phosphate (S1P) induces mitochondrial impairment in β-cells. (A) After incubation with a sphingosine kinase inhibitor (SphKi) and/or S1P for 48 hours, mouse insulinoma 6 (MIN6) cells were incubated with tetramethylrhodamine ethyl ester (TMRE) to evaluate the mitochondrial membrane potential. After washing with phosphate-buffered saline, the intensity of red fluorescence in the TMRE-stained cells was detected, and (B) represented by quantitative analysis. Bar=20 μm. (C) Expression of mitochondrial dynamin-like GTPase (OPA1) and mitofusin 1 (Mfn1), key molecules regulating mitochondrial fusion and fission, was analyzed by an immunoblotting assay, and (D) the ratio to β-actin was determined. (E, F) Mitochondrial proteins regulating oxidative phosphorylation (OxPHOS) were detected using an OxPHOS complex antibody cocktail by an immunoblotting assay, and the ratio to β-actin was determined. (G, H) Adenosine triphosphate (ATP) levels and the oxygen consumption rate in MIN6 cells treated with SphKi and/or S1P were compared. The amount of ATP is represented as the percent of control, and the rate of oxygen consumption is described as picomoles per minute. 
Knockdown of SphK2 reduces prohibitin expression and mitochondrial function
In this study, we found that S1P deficiency induced morphological and functional impairment of mitochondria in MIN6 cells, and we next investigated the mediator of the effects of S1P. Decreased levels of PHB, a pivotal regulator of mitochondrial function and dynamics, were detected in SphKi-treated MIN6 cells (Fig. 3A) . To confirm the interaction between S1P and PHB, we used specific siRNA for SPHK. We transfected siRNAs for SPHK1 and SPHK2, respectively, because there are two SphK isoforms that synthesize S1P. Interestingly, the expression of PHB was significantly repressed by transfection of siRNA for SPHK2, but knockdown of SPHK1 did not affect PHB expression, when compared to cells transfected with siscramble (Fig. 3B) . Knockdown of SPHK2 decreased cellular S1P levels, and PHB expression was also significantly repressed by SPHK2 knockdown (Fig. 3C, D) . Co-treatment with S1P dramatically blocked the decrease in PHB expression caused by Released insulin (μg/mL medium)
si-Scr/ S1P
si-Scr/ S1P SPHK2 knockdown, and the morphological and functional dysregulation of mitochondria caused by SPHK2 knockdown was remarkably ameliorated by S1P treatment, as shown by significant recovery of TMRE intensity, ATP content, and the oxygen consumption rate (Fig. 3E-G) . Knockdown of SPHK2 also affected β-cell function, consistent with SphKi treatment. Insulin secretion in medium containing 25 mmol/L glucose was decreased by si-SPHK2 transfection, and significantly recovered in S1P co-treated cells (Fig. 3H) .
The role of sphingosine-1-phosphate is mediated by prohibitin Finally, we evaluated the effect of S1P on regulating mitochondrial function in a PHB knockdown model to examine whether PHB mediated the effect of S1P on the mitochondria of β-cells. Transfection with siRNA for PHB significantly decreased the expression of PHB messenger RNA and protein (Fig. 4A, B) and repressed the MMP, as detected by TMRE staining (Fig.  4C) . Mitochondrial function was also down-regulated by PHB knockdown, as shown by decreases in ATP content and the oxygen consumption rate (Fig. 4D, E) . Moreover, PHB knockdown resulted in significant repression of GSIS (Fig. 4F) , and the mitochondrial dysregulation and the impairment of insulin secretion by PHB knockdown were not improved by additional treatment with S1P (Fig. 4) . These data suggest that PHB is an indispensable factor mediating the effects of S1P on mitochondrial regulation and insulin secretion.
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DISCUSSION
The current study demonstrated that S1P deficiency induced β-cell impairment and apoptosis via mitochondrial dysfunction and a decrease in PHB levels. Repression of S1P synthesis by treatment with SphKi or by siRNA for SPHK2 resulted in conspicuous β-cell dysfunction and apoptosis. It has been reported that S1P is important in GSIS of β-cells and the onset of diabetes [12] . In MIN6 cells, SphK2 activity was facilitated by high levels of glucose, inducing an increase in cellular S1P levels, and S1P was essential for maintaining GSIS [11] . Moreover, glucose was reported to alter S1P levels in endothelial cells and rat pancreatic islets [25, 26] . These data strongly suggest that S1P produced by SphK2 plays a pivotal role in the preservation of β-cell function and prevention of type 2 diabetes.
Our data demonstrated that treatment with SphKi caused severe dysregulation of morphological dynamics and function in β-cell mitochondria, as shown by reduced ATP production and oxygen consumption. The MMP, as detected by TMRE, decreased, and key components of mitochondrial dynamics, OPA1 and MFN1, were also significantly repressed by S1P deficiency (Fig. 2) , suggesting that S1P plays an essential role in maintaining mitochondrial homeostasis. S1P is an intracellular target that is involved in a variety of cellular signaling processes, and is produced anywhere in the cell, depending on the location of SphK [27] [28] [29] . It was reported that SphK2 was localized to the inner membrane of the mitochondria and regulated S1P levels, indicating the pivotal role of S1P in mitochondrial function [23] . As shown in Fig. 3A , knockdown of SphK1 had no effect on PHB expression, and cellular S1P levels were drastically decreased by SPHK2 knockdown, suggesting that SphK2 is a major regulator of cellular S1P levels in β-cells. Consistent with our data, a recent study demonstrated that SphK1 had insignificant effects on GSIS in MIN6 cells [11] , suggesting that S1P levels in specific locations or compartments, such as the mitochondria or granules, may be more important than the overall S1P levels throughout the cell.
This study also demonstrated that PHB played a role in the S1P-induced improvement of mitochondrial function and GSIS (Fig. 4) . PHB is known to be a key factor for regulating the proper development, morphogenic remodeling, and function of mitochondria [30, 31] . Knockdown of PHB dramatically reduced the mitochondrial function and membrane potential in MIN6 cells (Fig. 4D-F) . This is consistent with several previous reports indicating that PHB plays a function in mitochondrial biogenesis, based on the finding that PHB deficiency in plants led to repression of the MMP and oxygen consumption [32] . Moreover, PHB protected HeLa cells against apoptosis via interaction with Hax-1, and preserved mitochondrial morphology through regulation of OPA1 [33] .
In summary, the present study revealed that S1P plays a pivotal role in β-cell function and survival through regulating the expression of PHB and contributing to the maintenance of mitochondrial homeostasis, which is consistent with previous data that have demonstrated the essential function of S1P and PHB in cell metabolism. Furthermore, we showed that SphK2 is the main isoform that regulates cellular S1P levels and PHB expression in β-cells, suggesting that S1P may be a valuable target for potential strategies to prevent and treat type 2 diabetes.
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